{"response": {"meta": {"time": 28, "hits": 2, "offset": 0}, "docs": [{"news_desk": "Science Desk", "document_type": "article", "_id": "4fd1fb028eb7c8105d75923b", "headline": {"main": "Breast Cancer Drug Dilemma: Who Should Take It, and When?"}, "pub_date": "1998-04-14T00:00:00Z", "slideshow_credits": null, "source": "The New York Times", "byline": {"original": "By DENISE GRADY", "person": [{"lastname": "GRADY", "rank": 1, "firstname": "Denise", "organization": "", "role": "reported"}]}, "abstract": "Tamoxifen has been shown to have strong protective effect on women at high risk for breast cancer, but researchers have not yet analyzed enough data to develop recommendations on which women should take it and when; Dr Leslie Ford of National Cancer Institute says it hopes to have information available within 'weeks or months' that women and doctors could use to assess an individual woman's risk of developing breast cancer and of suffering serious side effects from tamoxifen, which include small increases in risk of blood clots, uterine cancer and depression; it will not be able to offer simple set of guidelines that would apply to everyone; photo; graph shows increase of breast cancer risk with age (M)", "web_url": "http://www.nytimes.com/1998/04/14/science/breast-cancer-drug-dilemma-who-should-take-it-and-when.html", "section_name": "Science; Health", "lead_paragraph": "WHEN Bernice Olson heard in 1992 that a nationwide study was under way to determine whether the drug tamoxifen could prevent breast cancer in high-risk women, she volunteered right away. One of her sisters, who is now healthy, had had the disease in 1980, at the age of 43. That, combined with Mrs. Olson's own age, 51, defined her as high risk. Last week she and others in the study received a letter marked ''urgent,'' notifying her that the experiment had been halted a year early, because tamoxifen had shown such a powerful protective effect -- 45 percent fewer cases of breast cancer in the women taking it -- that the scientists felt ethically bound to offer the drug to all the women in the study, some of whom had been assigned to a group that were taking placebos.", "snippet": "WHEN Bernice Olson heard in 1992 that a nationwide study was under way to determine whether the drug tamoxifen could prevent breast cancer in high-risk women, she volunteered right away. One of her sisters, who is now healthy, had had the disease in...", "blog": [], "keywords": [{"value": "FORD, LESLIE", "name": "persons"}, {"value": "NATIONAL CANCER INSTITUTE", "name": "organizations"}, {"value": "BREAST", "name": "subject"}, {"value": "DRUGS (PHARMACEUTICALS)", "name": "subject"}, {"value": "CANCER", "name": "subject"}, {"value": "WOMEN", "name": "subject"}, {"value": "DEPRESSION (MENTAL)", "name": "subject"}, {"value": "TAMOXIFEN (DRUG)", "name": "subject"}, {"value": "UTERUS", "name": "subject"}], "print_page": "1", "type_of_material": "News", "word_count": 1283, "subsection_name": null, "multimedia": []}, {"news_desk": "Business/Financial Desk", "document_type": "article", "_id": "4fd20beb8eb7c8105d77ac3e", "headline": {"main": "Predecessors' Woes Make Diet Drug a Tough Sell"}, "pub_date": "1998-04-11T00:00:00Z", "slideshow_credits": null, "source": "The New York Times", "byline": {"original": "By DANA CANEDY", "person": [{"lastname": "CANEDY", "rank": 1, "firstname": "Dana", "organization": "", "role": "reported"}]}, "abstract": "Knoll Pharmaceutical Co faces tough time winning acceptance of prescription diet pill Meridia because of health concerns about predecessor drugs dexfenfluramine (Redux) and fenfluramine (Pondimin), part of drug cocktail known as fen-phen; Knoll holds Meridia is as effective, but safer, than predecessors; some diet centers that enlisted doctors to prescribe earlier drugs say they will not offer Meridia; consumer advocates and doctors groups are advising overweight people to carefully weigh possible side effects; graphs (M)", "web_url": "http://www.nytimes.com/1998/04/11/business/predecessors-woes-make-diet-drug-a-tough-sell.html", "section_name": "Health; Business", "lead_paragraph": "Seven months after two popular prescription diet pills were yanked off the market because of health fears, another drug maker is trying to sell the public on the latest weight-loss medication. But just how does a pharmaceutical company market a pill that sounds a lot like something that has just been withdrawn? That is the challenge facing the Knoll Pharmaceutical Company, which contends that its drug, Meridia, is just as effective as Redux and Pondimin, half of the drug cocktail known as fen-phen, but safer to use. Those controversial drugs were in great demand last year until they were identified as a possible cause of heart-valve problems in some users.", "snippet": "Seven months after two popular prescription diet pills were yanked off the market because of health fears, another drug maker is trying to sell the public on the latest weight-loss medication.    But just how does a pharmaceutical company market a...", "blog": [], "keywords": [{"value": "KNOLL PHARMACEUTICAL CO", "name": "organizations"}, {"value": "WEIGHT", "name": "subject"}, {"value": "PONDIMIN (DRUG)", "name": "subject"}, {"value": "REDUX (DRUG)", "name": "subject"}, {"value": "DRUGS (PHARMACEUTICALS)", "name": "subject"}, {"value": "DEXFENFLURAMINE (DRUG)", "name": "subject"}, {"value": "FENFLURAMINE (DRUG)", "name": "subject"}, {"value": "MERIDIA (DRUG)", "name": "subject"}], "print_page": "1", "type_of_material": "News", "word_count": 1249, "subsection_name": null, "multimedia": []}]}, "status": "OK", "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}